CanAg® PSA EIA

PSA is a 32 kDa single-chain, glycoprotein serine protease with a chymotrypsin-like specificity produced by the secretory epithelium of the prostate gland1. PSA is normally secreted into the seminal fluid and plays a functional role in the cleavage of the seminal vesicle proteins and the liquefaction of the seminal coagulum2. Only low levels of PSA are normally present in the blood stream, and increasing serum concentrations indicate prostatic pathology, including benign prostatic hyperplasia and cancer of the prostate. Determination of PSA is now widely used for detection and management of patients with prostatic cancer and considered as the superior serological marker for cancer of the prostate3.

PSA has been shown to form stable complexes with different antiproteases and the dominating portion of PSA in patient serum occurs in complex with α1-antichymotrypsin (PSA-ACT)4. However there are large variations in the relation between Free PSA and PSA-ACT complex between different individuals. Studies have also indicated that the proportion of Free PSA is higher in benign prostatic disease as compared to prostatic cancer5. The antibodies in the PSA EIA have been carefully evaluated and selected to give the same molar response for Free PSA as for the PSA-ACT complex7. The PSA EIA thus gives a true “total” PSA value independent of the individual variations of free and ACT-complexed PSA. 
 

References

  1. Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979). Purification of a human prostate specific antigen. Invest Urol 17: 159-163.
  2. Lilja H. (1985). A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899-1903.
  3. Oesterling JE (1991). Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urology 145: 907-923.
  4. Lilja H., Christensson A., Dahlén U., Matikainen M-T, Nilsson O., Pettersson K., Lövgren T. (1991). Prostate-specific antigen in serum occurs predominantely in complex with α1-antichymotrypsin. Clin Chem 3 7: 1618-1625.
  5. Christensson A., Björk T., Nilsson O., Dahlén U., Matikainen M-T., Cockett ATK, Abrahamsson PA, Lilja H. (1993). Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urology 150: 100-105.
  6. Oesterling JE., Cooner WH., Jacobsen SJ., Guess HA., Lieber MM. (1993). The influence of patient age on the serum prostate specific antigen concentration: An important clinical observation. Urol Clin North Am 20: 671-80, 1 993a.
  7. Nilsson O., Peter A. Andersson I., Nilsson K., Grundström B., and Karlsson B. (1997) Antigenic determinants of prostatespecific antigen (PSA) and development of assays specific for different forms of PSA. Br J Cancer 75(6): 789-79
CE marked
CanAg PSA EIA

Product number 340-10

For 96 determinations
Contact sales for information and inquiries
Please contact your local Fujirebio representative for the availability of this product in your country.
  • Product inquiry

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.